Conversion from Cyclosporine to Tacrolimus improves Renal Function and Lipid Profile after Cardiac Transplantation
Miroslaw Garlicki, Pawel Czub, Krzysztof Labus, Marek P Ehrlich, Hanna RdzanekAnn Transplant 2006; 11(1): 24-27 :: ID: 496936
Abstract
Background: Calcineurin inhibitors (CNIs) have become the cornerstone of immunosuppressive regimens following heart transplantation, but their use is associated with nephrotoxicity. The impact on renal function after conversion from cyclosporine (CsA) to tacrolimus (TAC) is reported. Patients and methods: Fifteen patients (men age 42±11 years) after cardiac transplantation (HTX) were switched from CsA to TAC (mean time after HTX 21±6 month). There were 13 male and 2 female patients. Mean cholesterol and LDL level at the time of conversion were 217±65 ml/dl and and 136±51 mg/100ml respectively. Indication for HTX was ischemic cardiomyopathy (CMP) in 8, congenital in 3 and dilatative CMP in the remaining 4 patients. Results: Mean tacrolimus level (μg/dl) at 1, 3, 6 and 12 months were 8.6±3.3, 8.6±1.4, 9.2±2.8 and 9.8±2.5 respectively. There was a statistically significant improvement in creatinine levels at 1, 3, 6 and 12 months after conversion from baseline 1.9±0.7mg/dl to 1.4±0,5 mg/dl, 1.4±0.4 mg/dl, 1.3±0.4 mg/dl and 1.2±0.4 mg/dl, respectively (p< 0.05). Furthermore, TAC decreased cholesterol as well as LDL-levels during this one-year time frame. Conclusion: This study shows that conversion from CsA to tacrolimus after orthotopic heart transplantation improves renal function.
Keywords: Heart Transplantation, Renal Function, lipid profile
In Press
Original article
Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...Ann Transplant In Press; DOI: 10.12659/AOT.951568
Original article
Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver TransplantationAnn Transplant In Press; DOI: 10.12659/AOT.950589
Database Analysis
Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...Ann Transplant In Press; DOI: 10.12659/AOT.950289
Original article
Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...Ann Transplant In Press; DOI: 10.12659/AOT.950997
Most Viewed Current Articles
24 Aug 2021 : Review article 18,372
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
05 Apr 2022 : Original article 14,731
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 14,244
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
29 Dec 2021 : Original article 13,752
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588






